Key Highlights

● Edwards Lifesciences closed at $85.27 on 9 October 2026.

● Market data consensus target is $100.27, implying about 17.6% upside.

● The second data set shows a mean of $101.96 and a median of $102.50.

● BTIG reiterated its rating with a $110 target on 11 September.

Edwards Lifesciences (NYSE:EW), an S&P 500 member, closed at $85.27 on Friday 9 October 2026. The shares trade below almost every published analyst target, and ratings are mostly positive.

What Is the Latest Analyst Price Target?

Market data reports a consensus 12-month target of $100.27 from 22 analysts with ratings in the past 12 months. The highest target is $110 and the lowest is $85. The second data set shows a mean of $101.96, a median of $102.50, a high of $110 and a low of $84 from 29 analysts. The market data mean is a little below the average of the named broker targets issued since July, which is roughly $103, so the figures are broadly consistent.

What Are Wall Street Analysts Saying?

Sentiment is positive. Market data records 16 Buy ratings and one Strong Buy, five Hold ratings and no Sell ratings, giving a Moderate Buy consensus. The second data set shows 23 Buy or Strong Buy ratings, six Holds and no Sells.

Most named broker actions listed by market data date from July, with a few reiterations in October. UBS reiterated a Buy rating on 8 October, Barclays is listed as upgrading to Strong Buy on 7 October, and Citigroup reiterated a Buy rating on 5 October, but none of those entries gives a target. BTIG Research reiterated a Buy rating with a $110 target on 11 September. In July, RBC raised its target from $100 to $110 with an Outperform rating, Mizuho from $100 to $105 with an Outperform rating, JPMorgan from $100 to $105 with an Overweight rating, and Piper Sandler from $100 to $101 with an Overweight rating.

Leerink Partners upgraded the stock to Outperform from Market Perform and raised its target from $87 to $101 on 24 July. Truist Financial raised its target from $90 to $95 with a Hold rating on 16 July, and Evercore reiterated an Outperform rating with a $100 target on 6 July.

What Could Help the Stock Reach the Price Target?

The shares trade below almost every published target, with only the $85 low target close to the current price, so a re-rating would be needed to approach the consensus. Market data reports earnings per share of $0.78 against $0.74 expected and revenue of $1.74 billion, above expectations, for the latest quarter. If the company continues to meet or beat forecasts, brokers with Buy ratings may maintain or raise their targets.

What Could Prevent the Stock Reaching the Target?

The gap between the share price and most published targets is wide, which may indicate that investors are more cautious than analysts.

What Should Investors Watch Next?

Investors may watch whether brokers with Buy ratings maintain or raise their targets.

Edwards Lifesciences and the Case for a Re-Rating

Edwards Lifesciences closed at $85.27 on 9 October 2026, with the market data consensus of $100.27 implying about 17.6% upside. Only the $85 low target sits close to the share price.